Evidence map›Paper›PMID 41753671›Full record

ArticleMicroorganisms2026

Serum Uric Acid-Reducing Effect and Intestinal Mucosal Barrier-Repairing Function of

Jinhua Cheng, Youjin Lee, Joo-Hyung Cho, Joo-Won Suh

Abstract read
In one paragraph

Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jinhua ChengSchool of Pharmacy and Food Engineering, Wuyi University, Jiangmen 529000, China.ORCID 0000-0001-6172-6882
Youjin LeeMyongji Bioefficacy Research Center, Myongji University, Yongin 17058, Republic of Korea.ORCID 0000-0002-3752-3871
Joo-Hyung ChoMyongji Bioefficacy Research Center, Myongji University, Yongin 17058, Republic of Korea.ORCID 0000-0002-3955-0224
Joo-Won SuhMyongji Bioefficacy Research Center, Myongji University, Yongin 17058, Republic of Korea.ORCID 0000-0003-1085-2429

Funding

by the Basic Science Research Program through the NRF funded by the Ministry of Education (No. RS-2025-02663016). No. RS-2025-02663016This research was also supported by the Global - Learning & Academic research institution for Master's·PhD students, and Postdocs (LAMP) Program of the National Research Foundation of Korea (NRF) grant funded by the Ministry of Education No. RS-2023-00301938This research was funded by the Start-up Fund for Scientific Research of High-level Talents of Wuyi University. 510170040617This study was supported by R & D budget of MBHC Co. Ltd., Korea for development of functional probiotics and microbiome. MBHC001
6 · The paper itself

Abstract

Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid levels and is increasingly linked to alterations in intestinal mucosal condition and gut microbiota composition. Probiotics have been proposed as safe, non-pharmacological approaches for managing hyperuricemia, but strain-specific evidence remains limited. This study aimed to evaluate the anti-hyperuricemic potential of

Indexed as

hyperuricemiaintestinal barrierLimosilactobacillus reuterimicrobiotaprobiotics

Identifiers

PMID41753671
PMCPMC12942943

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.